NanoViricides to Present Antiviral Drug Pipeline at Spartan Capital Investor Conference

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antiviral drugs, announced it will present today, November 3, 2025, at 9:45 a.m. ET at the Spartan Capital Investor Conference in New York City. The presentation offers investors insight into the company's innovative approach to antiviral therapy at a time when global health systems continue to face challenges from emerging viral threats.

The company's nanoviricide technology platform represents a significant advancement in antiviral treatment development. Unlike traditional antiviral drugs that target specific viral enzymes, nanoviricides are designed to directly attack viruses by encapsulating them, potentially preventing viral escape and resistance development. This approach could address one of the major limitations of current antiviral therapies, where viruses often mutate to become resistant to existing treatments.

NanoViricides' lead drug candidate, NV-387, is being developed as a broad-spectrum antiviral treatment for respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is currently focused on advancing NV-387 into Phase II human clinical trials. Another advanced candidate, NV-HHV-1, targets shingles treatment, representing potential relief for millions affected by this painful condition.

The company's technology foundation comes from its relationship with TheraCour Pharma, Inc., from which NanoViricides has obtained broad, exclusive, sub-licensable field licenses for drugs developed in several licensed fields. The company's business model, established at its foundation in 2005, involves licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses. Additional information about the company's technology and programs is available at https://www.nanoviricides.com.

Beyond its lead candidates, NanoViricides is developing treatments for numerous other viral diseases including oral and genital herpes, viral eye diseases, various influenza strains, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. The company holds worldwide exclusive perpetual licenses for several drugs targeting specific viruses, including Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B and C viruses, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue viruses, and certain Coronaviruses.

The timing of this investor presentation is particularly relevant given the continued global need for effective antiviral treatments. The COVID-19 pandemic demonstrated how quickly viral threats can emerge and spread globally, highlighting the importance of developing broad-spectrum antiviral platforms that can be rapidly deployed against new viral threats. NanoViricides' approach of creating special purpose nanomaterials for antiviral therapy represents a novel strategy that could potentially address multiple viral families with a single platform technology.

Investors and industry observers can find the latest news and updates relating to NNVC in the company's newsroom at https://ibn.fm/NNVC. The company acknowledges the inherent risks in drug development, noting that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts, there can be no assurance that any of the company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development at this stage.